Phoremost Ltd News Today

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selectionLONDON, May 22, 2024 /PRNewswire/ -- NeoPhore

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

New drug discovery platform integrates computational approaches with molecular biology for development of novel degrader therapeutics PhoreMost Ltd., a leading UK biopharmaceutical company unlocking

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

PhoreMost Ltd. announced Professor Peter Parker and Dr Jason Imbriglio as members of its Scientific Advisory Board (SAB).

/PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement...

/PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B...

PhoreMost Ltd. and ThinkCyte K.K today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).

– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling...

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes